Reach Us +1 702 553-3066
Colorectal Cancer Screening: Is there a Role for Stool DNA Testing? | OMICS International | Abstract
ISSN: 2157-2518

Journal of Carcinogenesis & Mutagenesis
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Mini Review

Colorectal Cancer Screening: Is there a Role for Stool DNA Testing?

Laura Mazilu*, Andra-Iulia Suceveanu, Irinel-Raluca Parepa and Doina-Ecaterina Tofolean

Faculty of Medicine, Ovidius University, Clinical Emergency Hospital of Constanta, Romania

*Corresponding Author:
Laura Mazilu
Department of Oncology, Clinical Emergency Hospital of Constanta
Tomis Blvd. no. 145, 900591, Romania
Tel: 0241503444
E-mail: [email protected]

Received date: March 01, 2014; Accepted date: May 24, 2013; Published date:May 31, 2013

Citation: Mazilu L, Suceveanu AI, Parepa IR, Tofolean DE (2014) Colorectal Cancer Screening: Is there a Role for Stool DNA Testing?. J Carcinog & Mutagen S10:006. doi: 10.4172/2157-2518.S10-006

Copyright: © 2014 Mazilu L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world, being the third most common cancer in the world and the fourth most common cause of death. In recent years increased rates of CCR incidence has been reported in developing countries. The presence or absence of screening programs is an important factor in determining overall changes of CRC epidemiology. CCR screening modalities vary throughout the world, and the differences are probably due to the cost and availability of diagnostic resources. Colonoscopy, sigmoidoscopy, and FOBTs are all recommended screening tests, but adherence rates are low. Additional stoolbased methods that offer more options for CRC have been developed, including fecal DNA tests. Stool-based DNA testing is noninvasive, and it is more sensitive and specific than FOBTs, only a single stool sample is needed, the test does not require diet or medication restrictions, and it evaluates the whole colon and rectum. The disadvantages of stool-based DNA testing include: high cost, lower sensitivity comparing with colonoscopy, and the fact that if the stool-based test is positive, colonoscopy needs to be done anyway. Finally, relatively high rates of false-positive and false-negative results limit the accuracy of these tests, thereby restricting their widespread use.


Recommended Conferences
Share This Page